The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
ScienceAlert on MSN6d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
Verywell Health on MSN1d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
TheHealthSite.com on MSN6d
US FDA Approves First Of Its Kind Ketamine-Based Nasal Spray To Treat Depression: Know All About This DrugThe US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback